TY - JOUR
T1 - Nanocarriers for delivery of platinum anticancer drugs
AU - Oberoi, Hardeep S.
AU - Nukolova, Natalia V.
AU - Kabanov, Alexander V.
AU - Bronich, Tatiana K.
N1 - Funding Information:
This work was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant P20GM103480 , the Russian Federation Ministry of Science and Education grant 11.G34.31.0004 , the grants from the President of Russia for Young Scientists ( МК-7114.2012.7 ) and from Russian Foundation for Basic Research ( 12-04-31731 ). We thank Professor Kazunori Kataoka (The University of Tokyo, Japan) for his advice and communication of most recent data from his group. We are grateful to Dr. D. Alakhova for her assistance in the preparation of illustrations for this review.
PY - 2013
Y1 - 2013
N2 - Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.
AB - Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.
KW - Block ionomer complex
KW - Dendrime
KW - Drug delivery systems
KW - Liposome
KW - Micelle
KW - Nanoparticle
KW - Nanotube
KW - Platinum drugs
KW - Polymer conjugate
UR - http://www.scopus.com/inward/record.url?scp=84888199191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888199191&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2013.09.014
DO - 10.1016/j.addr.2013.09.014
M3 - Review article
C2 - 24113520
AN - SCOPUS:84888199191
VL - 65
SP - 1667
EP - 1685
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
IS - 13-14
ER -